Cargando…
Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application
Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 vaccine. The major obstacle to the development of HIV-1 vaccine is the extreme diversity of viral genome sequences. Nonet...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329590/ https://www.ncbi.nlm.nih.gov/pubmed/34354709 http://dx.doi.org/10.3389/fimmu.2021.697683 |
_version_ | 1783732540516859904 |
---|---|
author | Ding, Chengchao Patel, Darshit Ma, Yunjing Mann, Jamie F. S. Wu, Jianjun Gao, Yong |
author_facet | Ding, Chengchao Patel, Darshit Ma, Yunjing Mann, Jamie F. S. Wu, Jianjun Gao, Yong |
author_sort | Ding, Chengchao |
collection | PubMed |
description | Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 vaccine. The major obstacle to the development of HIV-1 vaccine is the extreme diversity of viral genome sequences. Nonetheless, a number of broadly neutralizing antibodies (bNAbs) against HIV-1 have been made and identified in this area. Novel strategies based on using these bNAbs as an efficacious preventive and/or therapeutic intervention have been applied in clinical. In this review, we summarize the recent development of bNAbs and its application in HIV-1 acquisition prevention as well as discuss the innovative approaches being used to try to convey protection within individuals at risk and being treated for HIV-1 infection. |
format | Online Article Text |
id | pubmed-8329590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83295902021-08-04 Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application Ding, Chengchao Patel, Darshit Ma, Yunjing Mann, Jamie F. S. Wu, Jianjun Gao, Yong Front Immunol Immunology Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 vaccine. The major obstacle to the development of HIV-1 vaccine is the extreme diversity of viral genome sequences. Nonetheless, a number of broadly neutralizing antibodies (bNAbs) against HIV-1 have been made and identified in this area. Novel strategies based on using these bNAbs as an efficacious preventive and/or therapeutic intervention have been applied in clinical. In this review, we summarize the recent development of bNAbs and its application in HIV-1 acquisition prevention as well as discuss the innovative approaches being used to try to convey protection within individuals at risk and being treated for HIV-1 infection. Frontiers Media S.A. 2021-07-20 /pmc/articles/PMC8329590/ /pubmed/34354709 http://dx.doi.org/10.3389/fimmu.2021.697683 Text en Copyright © 2021 Ding, Patel, Ma, Mann, Wu and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ding, Chengchao Patel, Darshit Ma, Yunjing Mann, Jamie F. S. Wu, Jianjun Gao, Yong Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application |
title | Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application |
title_full | Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application |
title_fullStr | Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application |
title_full_unstemmed | Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application |
title_short | Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application |
title_sort | employing broadly neutralizing antibodies as a human immunodeficiency virus prophylactic & therapeutic application |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329590/ https://www.ncbi.nlm.nih.gov/pubmed/34354709 http://dx.doi.org/10.3389/fimmu.2021.697683 |
work_keys_str_mv | AT dingchengchao employingbroadlyneutralizingantibodiesasahumanimmunodeficiencyvirusprophylactictherapeuticapplication AT pateldarshit employingbroadlyneutralizingantibodiesasahumanimmunodeficiencyvirusprophylactictherapeuticapplication AT mayunjing employingbroadlyneutralizingantibodiesasahumanimmunodeficiencyvirusprophylactictherapeuticapplication AT mannjamiefs employingbroadlyneutralizingantibodiesasahumanimmunodeficiencyvirusprophylactictherapeuticapplication AT wujianjun employingbroadlyneutralizingantibodiesasahumanimmunodeficiencyvirusprophylactictherapeuticapplication AT gaoyong employingbroadlyneutralizingantibodiesasahumanimmunodeficiencyvirusprophylactictherapeuticapplication |